NOVO NORDISK A S
NONOFDrugs in Pipeline
59
Phase 3 Programs
48
Upcoming Catalysts
9
Next Catalyst
Sep 2026
Market Overview
Stock performance and key metrics
9 upcoming, 0 past
insulin degludec
Diabetes
eptacog alfa (activated)
Acquired Bleeding Disorder
IcoSema
Diabetes Mellitus, Type 2
Concizumab
Haemophilia A With Inhibitors
NNC0487-0111
Obesity
estradiol, 10 mcg
Menopause
Norditropin®
SGA, Turner Syndrome, Noonan Syndrome, ISS
biphasic insulin aspart 50
Diabetes
estradiol, 25 mcg
Menopause
pioglitazone
Diabetes
semaglutide 2.4 mg
Obesity
activated recombinant human factor VII
Acquired Bleeding Disorder
human soluble insulin
Diabetes
Cagrilintide
Obesity
insulin aspart
Diabetes
liraglutide
Diabetes
insulin degludec/liraglutide
Diabetes
Mim8
Haemophilia A With or Without Inhibitors
rosiglitazone
Diabetes
insulin degludec/insulin aspart
Diabetes
Ziltivekimab
Cardiovascular Risk
biphasic insulin aspart
Diabetes
Insulin Icodec
Diabetes Mellitus, Type 2
biphasic human insulin
Diabetes
Semaglutide
Diabetes Mellitus, Type 2
catridecacog
Congenital Bleeding Disorder
Turoctocog alfa pegol
Congenital Bleeding Disorder
Somapacitan
Growth Hormone Deficiency in Children
insulin detemir
Diabetes
metformin
Diabetes
insulin glargine
Diabetes
human insulin
Diabetes
sitagliptin
Diabetes
biphasic insulin aspart 30
Diabetes
NPH insulin
Diabetes Mellitus, Type 1
Faster-acting insulin aspart
Diabetes
insulin NPH
Diabetes
NNC6019-0001
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Nonacog beta pegol
Haemophilia B
glimepiride
Diabetes
biphasic insulin aspart 70
Diabetes
turoctocog alfa
Congenital Bleeding Disorder
Oral semaglutide
Obesity
somatropin
Growth Hormone Disorder
DCR-PHXC
Primary Hyperoxaluria Type 1
Dulaglutide
Diabetes
exenatide
Diabetes
Tirzepatide
Obesity
recombinant interleukin-21
Cancer
vatreptacog alfa (activated)
Congenital Bleeding Disorder
NNC0114-0006
Inflammation
Insulin glargine U100
Diabetes Mellitus, Type 2
inhaled human insulin
Diabetes
NNC0519-0130
Obesity
EX1000
Diabetes
CagriSema (Cagrilintide B and Semaglutide I)
Diabetes Mellitus, Type 2
Etavopivat
Sickle Cell Disease
NNC0662-0419
Diabetes Mellitus, Type 2
NNC126-0083
Growth Hormone Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
insulin degludec | Phase 3 | Diabetes | - | - |
eptacog alfa (activated) | Phase 3 | Acquired Bleeding Disorder | - | - |
IcoSema | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Concizumab | Phase 3 | Haemophilia A With Inhibitors | - | - |
NNC0487-0111 | Phase 3 | Obesity | - | - |
estradiol, 10 mcg | Phase 3 | Menopause | - | - |
Norditropin® | Phase 3 | SGA, Turner Syndrome, Noonan Syndrome, ISS | - | - |
biphasic insulin aspart 50 | Phase 3 | Diabetes | - | - |
estradiol, 25 mcg | Phase 3 | Menopause | - | - |
pioglitazone | Phase 3 | Diabetes | - | - |
semaglutide 2.4 mg | Phase 3 | Obesity | - | - |
activated recombinant human factor VII | Phase 3 | Acquired Bleeding Disorder | - | - |
human soluble insulin | Phase 3 | Diabetes | - | - |
Cagrilintide | Phase 3 | Obesity | - | - |
insulin aspart | Phase 3 | Diabetes | - | - |
liraglutide | Phase 3 | Diabetes | - | - |
insulin degludec/liraglutide | Phase 3 | Diabetes | - | - |
Mim8 | Phase 3 | Haemophilia A With or Without Inhibitors | - | - |
rosiglitazone | Phase 3 | Diabetes | - | - |
insulin degludec/insulin aspart | Phase 3 | Diabetes | - | - |
Ziltivekimab | Phase 3 | Cardiovascular Risk | - | - |
biphasic insulin aspart | Phase 3 | Diabetes | - | - |
Insulin Icodec | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
biphasic human insulin | Phase 3 | Diabetes | - | - |
Semaglutide | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
catridecacog | Phase 3 | Congenital Bleeding Disorder | - | - |
Turoctocog alfa pegol | Phase 3 | Congenital Bleeding Disorder | - | - |
Somapacitan | Phase 3 | Growth Hormone Deficiency in Children | - | - |
insulin detemir | Phase 3 | Diabetes | - | - |
metformin | Phase 3 | Diabetes | - | - |
insulin glargine | Phase 3 | Diabetes | - | - |
human insulin | Phase 3 | Diabetes | - | - |
sitagliptin | Phase 3 | Diabetes | - | - |
biphasic insulin aspart 30 | Phase 3 | Diabetes | - | - |
NPH insulin | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Faster-acting insulin aspart | Phase 3 | Diabetes | - | - |
insulin NPH | Phase 3 | Diabetes | - | - |
NNC6019-0001 | Phase 3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | - | - |
Nonacog beta pegol | Phase 3 | Haemophilia B | - | - |
glimepiride | Phase 3 | Diabetes | - | - |
biphasic insulin aspart 70 | Phase 3 | Diabetes | - | - |
turoctocog alfa | Phase 3 | Congenital Bleeding Disorder | - | - |
Oral semaglutide | Phase 3 | Obesity | - | - |
somatropin | Phase 3 | Growth Hormone Disorder | - | - |
DCR-PHXC | Phase 3 | Primary Hyperoxaluria Type 1 | - | - |
Dulaglutide | Phase 3 | Diabetes | - | - |
exenatide | Phase 3 | Diabetes | - | - |
Tirzepatide | Phase 3 | Obesity | - | - |
recombinant interleukin-21 | Phase 2 | Cancer | - | - |
vatreptacog alfa (activated) | Phase 2 | Congenital Bleeding Disorder | - | - |
NNC0114-0006 | Phase 2 | Inflammation | - | - |
Insulin glargine U100 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
inhaled human insulin | Phase 2 | Diabetes | - | - |
NNC0519-0130 | Phase 2 | Obesity | - | - |
EX1000 | Phase 2 | Diabetes | - | - |
CagriSema (Cagrilintide B and Semaglutide I) | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Etavopivat | Phase 2 | Sickle Cell Disease | - | - |
NNC0662-0419 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
NNC126-0083 | Phase 2 | Growth Hormone Disorder | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in NOVO NORDISK A S's drug pipeline?→
CatalystAlert tracks 59 drug candidates in NOVO NORDISK A S's (NONOF) pipeline across Phase 3, Phase 2. Its lead program is insulin degludec (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NOVO NORDISK A S's next FDA catalyst?→
NOVO NORDISK A S's (NONOF) next tracked catalyst is a Phase 2 expected September 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NONOF biotech catalysts?→
Add NONOF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NOVO NORDISK A S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.